USPTO Examiner RZECZYCKI PHILLIP MATTHEW - Art Unit 1625

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18903345PYRIDO[4,3-D]PYRIMIDINE COMPOUNDSOctober 2024December 2024Allow210YesNo
18297081OPIOID RECEPTOR MODULATORSApril 2023September 2024Allow1701NoNo
18164813RAS INHIBITORSFebruary 2023October 2024Allow2100NoNo
18155343A METHOD FOR MANUFACTURING DEUTERATED BORON COMPOUNDJanuary 2023June 2025Abandon2920NoNo
18080744METHOD FOR SYNTHESIZING AN ANTI-CANCER COMPOUND THROUGH A ONE-POT REACTIONDecember 2022February 2025Abandon2610NoNo
17982452ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (MDAI)November 2022March 2025Abandon2810NoNo
17875776GPR119 AGONISTSJuly 2022June 2024Allow2210NoNo
17639154P-GP INDUCERS AS PROTECTORS AGAINST CHEMOTHERAPY-INDUCED SIDE EFFECTS, SUCH AS PERIPHERAL NEUROPATHY (CIPN) AND HAIR LOSSFebruary 2022June 2025Allow4010YesNo
17590603METHODS OF TREATING CANCERFebruary 2022June 2025Abandon4010NoNo
176290751,2-BIS(DIPHENYLPHOSPHINOALKYLAMIDO)-1,2-DISUBSTITUTED ETHANE, AND ITS SYNTHESIS AND APPLICATIONJanuary 2022December 2024Allow3511YesNo
176286597,8-DIHYDRO-4H-PYRAZOLO[4,3-c]AZEPINE-6-ONE COMPOUNDSJanuary 2022June 2025Abandon4110NoNo
17627275METHOD FOR OBTAINING AMORPHOUS REMIMAZOLAM BESYLATEJanuary 2022March 2025Allow3810NoNo
17625487COMPOSITION COMPRISING O-CYCLIC PHYTOSPHINGOSINE-1-PHOSPHATE FOR PREVENTING OR TREATING PARKINSON'S DISEASEJanuary 2022March 2025Allow3810YesNo
17624052INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOFDecember 2021June 2025Abandon4201NoNo
17557008CAMPTOTHECIN-BASED DIMER COMPOUND, ANTICANCER DRUG AND METHOD OF ELIMINATING CANCER STEM CELLDecember 2021May 2025Abandon4010NoNo
17644187NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIADecember 2021March 2025Allow3910NoNo
17596151PYRROLOPYRIMIDINE COMPOUND AND USE THEREOFDecember 2021April 2025Allow4010NoNo
17596023NON-HYGROSCOPIC CRYSTALLINE SALTS OF A PYRAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOFDecember 2021May 2025Allow4210NoNo
17614240COMPOUND AND PRODUCTION METHOD THEREOF, AFX-TYPE ZEOLITE AND PRODUCTION METHOD THEREOF, AND HONEYCOMB STACKED CATALYSTNovember 2021April 2025Abandon4110NoNo
17613648BISAMINOQUINOLINES AND BISAMINOACRIDINES COMPOUNDS AND METHODS OF THEIR USENovember 2021March 2025Allow4011NoNo
17529617SYNERGISTIC MIXTURES FOR FUNGAL CONTROLS IN CEREALSNovember 2021October 2024Allow3541YesNo
17607940MODULATORS OF TREX1November 2021March 2025Abandon4101NoNo
17513232IONIC CHANNEL MODULATION AS A METHOD FOR TREATING TUMORS THROUGH INFLAMMASOME ACTIVATIONOctober 2021January 2025Allow3810YesNo
17607325PIM KINASE INHIBITOR COMPOSITIONS AND USES THEREOFOctober 2021April 2025Abandon4101NoNo
17606827POLYMORPHS OF 7-CYCLOPENTYL-N,N-DIMETHYL-2-{[5-(PIPERAZIN-1-YL) PYRIDIN-2-YL]-AMINO}-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR THE PREPARATION THEREOFOctober 2021December 2024Allow3810NoNo
17606658A GRK2 PROTEIN INHIBITOR COMPOUND AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAMEOctober 2021April 2025Abandon4110NoNo
17606154SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORSOctober 2021March 2025Allow4111NoNo
17606026COMBINATION THERAPEUTIC REGIMENS WITH 1,6-DIBROMO-1,6-DIDEOXY-DULCITOLOctober 2021May 2025Abandon4210NoNo
17604540MANUFACTURING PROCESS FOR AMIFAMPRIDINE PHOSPHATEOctober 2021March 2025Abandon4110NoNo
17603550CD73 INHIBITORSOctober 2021June 2025Abandon4401NoNo
17435262PROCESS FOR THE SYNTHESIS OF VORTIOXETINEAugust 2021December 2024Allow4001NoNo
17420389FLUORINE-CONTAINING SUBSTITUTED BENZOTHIOPHENE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOFJuly 2021March 2025Allow4421YesNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner RZECZYCKI, PHILLIP MATTHEW - Prosecution Strategy Guide

Executive Summary

Examiner RZECZYCKI, PHILLIP MATTHEW works in Art Unit 1625 and has examined 31 patent applications in our dataset. With an allowance rate of 54.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner RZECZYCKI, PHILLIP MATTHEW's allowance rate of 54.8% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by RZECZYCKI, PHILLIP MATTHEW receive 0.94 office actions before reaching final disposition. This places the examiner in the 10% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by RZECZYCKI, PHILLIP MATTHEW is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +56.0% benefit to allowance rate for applications examined by RZECZYCKI, PHILLIP MATTHEW. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.